
Investors are infatuated lately with preclinical biotech companies going public.
Six of these very young biotechs have managed successful initial public offerings this year, despite not yet securing regulators’ permission to start human clinical trials. By comparison, one preclinical biotech was able to go public last year.
More opportunities for leveraged shorting down the line, eh Adam? As a lot, investors will lose money. see Feuerstein-Ratain rule. More Aeterna Zentaris companies here than future Amgens for sure.